A carregar...
Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results
IMPORTANCE: Brentuximab vedotin is a monomethyl auristatin E–conjugated monoclonal antibody directed against CD30. It represents a potential treatment for the CD30(+) lymphoproliferative disorder lymphomatoid papulosis (LyP), which currently has no approved treatment. OBJECTIVE: To assess the effica...
Na minha lista:
| Publicado no: | JAMA Dermatol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5817433/ https://ncbi.nlm.nih.gov/pubmed/28980004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2017.3593 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|